Hungerford Brian

CFO Brian Hungerford bought 4,000 shares in 2 transactions for $8,801.67, raising stake to 64,933 shares as stock trades -37.0% from 52-week high.

Brian Hungerford, CFO of unprofitable Kiromic Biopharma (net income $-6.8M over most recent full fiscal year), purchased 258 shares at $2.25 on 2024-08-19 and 3,742 shares at $2.20 on 2024-08-20, for a total of 4,000 shares at a blended average price of $2.20. At the current price of $2.18, the stock stands -37.0% from its 52-week high of $3.46. His prior trades at KRBP show negative 30-day returns: -32.7% on a 2024-06-13 purchase and -45.0% on a 2024-06-12 purchase, with 0 of 0 prior buys at this ticker well-timed at the 90-day mark. Across all tickers, his 3 prior open-market buys averaged a 30-day return of -38.8%, indicating a pattern of purchasing into weakness that has not subsequently recovered on his timeline. The timing and price context—buying near 52-week lows in a loss-making company—merit monitoring of whether this accumulation reflects either informational asymmetry or conviction that materializes.

CFO Hungerford buys 2,000 shares of KRBP at $1.75; stock down 49.4% from 52-week high and 16.7% in 30 days.

Brian Hungerford, CFO of Kiromic Biopharma, purchased 2,000 shares at $1.75 on 2024-08-13, increasing his holdings to 60,933 shares. The transaction occurs amid significant stock deterioration: the stock is down 49.4% from its 52-week high of $3.46 and declined 16.7% in the 30 days prior to the purchase. His prior trades at KRBP show a troubling pattern—two prior buys in June 2024 recorded 30-day losses of 32.7% and 45.0% respectively. More broadly, his cross-ticker track record shows 2 prior open-market buys with an average 30-day return of -38.8%, and zero of his prior buys were well-timed at the 90-day mark. The company itself is unprofitable with a net loss of $6.8M over its most recent full fiscal year and a market capitalization of only $2.7M, which limits the analytical utility of this small-position addition.